Older adults have an increased risk of COVID-19, so it's crucial that vaccines against the disease are effective in this age group.
"We're really delighted with the results".
Immune responses from vaccines tend to lessen as people get older as the immune system gradually slows with age.
"And the first data are really encouraging".
"We were pleased to see that our vaccine was not only well-tolerated in older adults; it also stimulated similar immune responses to those seen in younger volunteers".
Those earlier findings are based on a Phase II trial of 560 people, including 240 over the age of 70.
Within each of these groups, participants were randomised to receive either the Oxford vaccine, or a control vaccine (the meningococcal conjugate vaccine) which wouldn't provide protection against SARS-CoV-2.
Klay Thompson suffers right leg injury, will undergo MRI
In a devastating turn of events, this will no longer happen as Thompson recently tore his Achilles during a practice session . Based on the type of tear, Thompson has been told to expect that he will make a full recovery, a source tells ESPN.
Volunteers got two doses of the vaccine or a placebo, and no serious side effects related to the vaccine were reported, the researchers said.
These trial results from the University of Oxford, peer-reviewed in the Lancet, suggest that may not be a problem.
Besides the recipients of the Sinopharm jabs, authorities in Zhejiang said they had made a COVID-19 vaccine developed by the privately owned pharmaceutical company Sinovac Biotec available to high-risk groups in the east China province under the emergency use scheme.
Two weeks after the second dose, more than 99% of participants had neutralising antibody responses. Drugmaker AstraZeneca is working with the university on the vaccine.
The survey showed almost 29 per cent of Australians said they were "likely " to get a vaccine but were still "not certain" with the researchers classifying this position as hesitant.
"I think we're still at the bottom of that mountain in some ways", he said. The human body can become immune to the adenoviral vectors used in the vaccine, which makes booster shots more hard.
"Up until now, we've looked at antibody, which protects the circulating fluid (blood and tissue flow) from the virus".
The study also found that the vaccine was less likely to cause local reactions at the site where the injection was administered and symptoms on the day of vaccination in older adults than in the younger group.